The Enterprise Software segment continues to perform well. In comparing our first half figures to last year, it is important to remember that the largest trade fair for the printing industry, Drupa, took place in May and June of 2024. Hybrid Software closed a lot of business during Drupa but that left the sales pipeline relatively weak in the third quarter, and we did not see a recovery until October of last year. The current situation is much better. Enterprise Software sales increased more than 7% in the ...

Group 1 - AMG Critical Materials N.V. will release its second quarter 2025 financial results on July 30, 2025, at approximately 18:00 CEST, followed by a conference call on July 31, 2025, at 09:00 CEST to discuss these results [1] - The company focuses on providing critical materials and related process technologies aimed at advancing a less carbon-intensive world, particularly in energy storage materials such as lithium, vanadium, and tantalum [2] - AMG operates globally with approximately 3,600 employees and has production facilities in multiple countries including Germany, the United Kingdom, France, the United States, China, Mexico, Brazil, India, and Sri Lanka [4] Group 2 - AMG's Lithium segment aims to reduce the CO2 footprint across the lithium value chain, while the Vanadium segment is a market leader in recycling vanadium from oil refining residues [3] - The Technologies segment is recognized as a world market leader in advanced metallurgy, providing engineering services to the aerospace engine sector and supporting the development of LIVA batteries and NewMOX SAS for the nuclear fuel market [3]

Core Points - Fnac Darty is continuing its share buyback program authorized by the Annual General Meeting of Shareholders on May 28, 2025, for a total of 600,000 shares [2] - An amendment to the purchase agreement with Natixis was signed, maintaining the original terms, including a maximum unit purchase price of €80 [2] - The deadline for the buyback program has been extended to September 30, 2025, with the maximum amount to be purchased increased to €10 million [4]

Core Insights - Ipsos reported a revenue of €1,155.0 million for the first half of 2025, reflecting a total growth of 1.5% despite a challenging macroeconomic environment [2][3] - The company experienced a return to organic growth in the second quarter, achieving 0.7% organic growth after a decline of -1.8% in the first quarter [3][4] - The CEO emphasized ongoing investments in technology and artificial intelligence, alongside a commitment to acquisitions, while maintaining cautious optimism regarding the macroeconomic context [4][35] Financial Performance - Total revenue for the first half of 2025 was €1,155.0 million, with a gross margin of 68.4%, slightly down from 68.5% in the previous year [17][21] - Operating profit decreased by 17.0% to €95.5 million, resulting in an operating margin of 8.3% compared to 10.1% in the same period last year [17][26] - Net profit attributable to owners of the parent was €53.2 million, down from €78.0 million in the previous year, with adjusted net profit at €72.2 million, a decrease of 12.3% [26][41] Performance by Region - EMEA region showed total growth of 6.3% in the first half, with organic growth of 0.8%, driven by the integration of infas in Germany [6][7] - The Americas experienced a decline of -2.3% in total growth, but organic growth improved to 0.6% in the second quarter, particularly in the United States [8][9] - Asia-Pacific faced challenges with a total growth decline of -3.6%, attributed to a lack of recovery in China and uncertainties in the region [9] Performance by Audience - The consumer segment reported organic growth of 0.5% in the first half, with a notable improvement to 1.6% in the second quarter [12] - The citizens segment saw a significant decline of -11.4% in organic growth, impacted by uncertainties related to electoral cycles [13] - The doctors and patients audience experienced organic growth of 5.3%, supported by innovations in healthcare [14] Strategic Developments - Ipsos is pursuing an acquisition strategy, including the finalization of the acquisition of The BVA Family, enhancing capabilities in various markets [33] - The company is also focusing on advancements in technology and artificial intelligence, particularly in synthetic data solutions [34] - A new strategic plan, Horizons 2030, is set to be presented during an Investor Day on November 19, 2025 [36]

Core Viewpoint - Bilendi reported a significant revenue increase of 42.2% for the first half of 2025, driven by the acquisition of Netquest and strong international sales growth [2][3][4]. Financial Performance - Total revenue for H1 2025 reached €43.5 million, up from €30.6 million in H1 2024, reflecting a growth of 42.2% [3][4]. - International revenue surged by 55.0% to €36.4 million, accounting for 84% of total sales, compared to 77% in H1 2024 [5]. - Revenue in France, which represents 16% of total sales, increased slightly by 0.2% to €7.1 million, with a rebound of 4% in Q2 2025 [6]. Strategic Developments - The acquisition of Netquest, finalized in February 2025, is a key milestone for Bilendi, enhancing its position as a global leader in the market research sector [4][12]. - Bilendi is expanding its proprietary panel coverage, aiming to launch 20 new panels and increase its network to 50 countries by the end of 2025 [8]. - The company introduced the Bilendi Platform, a self-service solution for market research, and enhanced the Bilendi Discuss platform with AI capabilities for automated analysis [9][10]. Company Milestones - 2025 marks the 20th anniversary of Bilendi's listing on the Euronext Growth market, highlighting its transformation from an online loyalty program pioneer to a leader in technology and data solutions [11][12]. - Bilendi aims to achieve a revenue target of €100 million by 2026, with an EBITDA margin of 20% to 25% [13].

Nanterre, July 21st, 2025 Disclosure of transactions in on shares from July 14th to July 18th,2025 Within the framework of the authorization granted by the General Meeting of VINCI SA of April 17th, 2025, to trade in its shares and in accordance with the regulations relating to share buybacks, VINCI SA (LEI:213800WFQ334R8UXUG83) declares the purchases of treasury shares below (FR0000125486), carried out from July 14th to July 18th,2025: I - Aggregate presentation by day and by market Issuer’s nameDate of ...

Core Insights - The company reported a revenue increase of 32.2% in H1 2025 compared to H1 2024, reaching €4,480 million, with a like-for-like (LFL) growth of 0.7% [5][46] - The gross margin rate improved by 60 basis points to 28.9% in H1 2025, driven by the growing contribution of services [8][46] - The new strategic plan, "Beyond Everyday," aims to enhance circularity, service growth, customer experience, and European consolidation by 2030 [2][31] Financial Performance - In Q2 2025, revenue was €2,166 million, reflecting a 35.7% increase on a reported basis and 2.1% on a like-for-like basis compared to Q2 2024 [4][42] - Current EBITDA for H1 2025 was €189 million, showing a slight growth compared to H1 2024 [9][46] - The current operating income for H1 2025 was -€56 million, a decline from -€49 million in H1 2024 [10][43] Revenue Breakdown - Online sales grew by nearly 8% in H1 2025, accounting for 21% of total sales, with omnichannel sales remaining stable [11] - Services experienced double-digit growth across most regions, while gaming and domestic appliances were key drivers of revenue [12][13] - The Rest of Europe saw a 0.9% increase in LFL revenue, with notable growth in Spain (+7.4%) and Portugal (+4.6%) [17] Strategic Initiatives - The integration of Unieuro is ongoing, with a target of achieving at least €20 million in synergies by the end of 2026 [27] - The company aims to consolidate its omnichannel and service-based model across Europe, focusing on premium and sustainable products [30][31] - Environmental goals include a 50% reduction in direct CO₂ emissions by 2030 compared to 2019 levels [34][56] Financial Structure - Free cash flow from operations, excluding IFRS 16, was -€878 million in H1 2025, compared to -€736 million in H1 2024 [20] - The net financial debt, excluding IFRS 16, stood at €779 million as of June 30, 2025 [21] - The company maintains a strong liquidity position with a net cash position of €359 million and access to a €600 million revolving credit facility [22] Future Outlook - The company expects the operating margin to increase by 15 basis points to 2.0% by the end of 2025 [37] - Financial targets for 2025-2030 include a cumulative operational free cash flow of at least €1.2 billion and a capital allocation strategy prioritizing organic growth and shareholder returns [31][56]

View photos from the event here About Mariachi Fortunes Trio™ LAS VEGAS, July 23, 2025 (GLOBE NEWSWIRE) -- AGS, a global gaming supplier, partnered with Yaamava' Resort & Casino at San Manuel in Southern California and Palms Casino Resort in Las Vegas to debut its newest slot family, Mariachi Fortunes Trio™, in a first-of-its-kind, bi-state world premiere. On July 22, each property hosted a launch celebration inspired by one of the game's two energetic themes. Yaamava' Resort & Casino showcased Fiesta de lo ...

Device Offers Knob Option for Easy Finger Setting, Variety of Pin Configurations in Top and Side Adjustment Styles MALVERN, Pa., July 23, 2025 (GLOBE NEWSWIRE) -- Vishay Intertechnology, Inc. (NYSE: VSH) today introduced a new industrial-grade 3/8 inch square single-turn cermet trimmer. Available with an extended shaft, cross-slot rotor, or knob option for easy finger setting, the Vishay Sfernice M61 is offered in several pin configurations in both top and side adjustment styles to optimize placement on the ...

Core Points - NeOnc Technologies Holdings, Inc. is a clinical-stage biotechnology company focused on developing treatments for brain and central nervous system cancers [1][4] - The company will have its Executive Chairman, Amir Heshmatpour, featured in a live interview on July 24, 2025, at 11:00 a.m. ET [1] - NeOnc has executed a Sub-License Agreement with its Abu Dhabi subsidiary, NuroCure, as part of a $50 million strategic partnership with Quazar Investment [2] - The company has been included in the Russell Microcap Index, which is part of its strategy to attract institutional capital and enhance market liquidity [3] Company Overview - NeOnc Technologies is dedicated to developing and commercializing therapeutics that address challenges in overcoming the blood-brain barrier [4] - The company's NEO™ drug development platform has produced a portfolio of novel drug candidates with patent protections extending to 2038 [4] - NeOnc's NEO100™ and NEO212™ therapeutics are currently in Phase II human clinical trials and have received FDA Fast-Track and Investigational New Drug (IND) status [4]